Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Thoracic 1Sarcoma 1Genitourinary 1CNS 1

Conditions

Ovarian Neoplasms 2Carcinoma, Ovarian Epithelial 2

Interventions

Cisplatin 63Paclitaxel 56Carboplatin 38Taxes 24Radiotherapy 21Gemcitabine 16Brachytherapy 15Filgrastim 14Doxorubicin 13Topotecan 12Platinum 121,2-diaminocyclohexaneplatinum II citrate 12Docetaxel 11Radiation 7Granulocyte Colony-Stimulating Factor 7Chemotherapy, Adjuvant 7pegfilgrastim 6Surgical Procedures, Operative 6Radiotherapy, Intensity-Modulated 6Polymerase Chain Reaction 6Ifosfamide 6Etoposide 6Watchful Waiting 5Radiotherapy, Conformal 5Pemetrexed 5Gene Expression Profiling 5Fluorouracil 5Celecoxib 5Amifostine 5Observation 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × rubitecan × Gynecologic × Clear all
NCT00006267 2013-07-09

Nitrocamptothecin in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer

GOG Foundation

Phase 2 Withdrawn
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00006230 2012-09-24

Nitrocamptothecin in Treating Patients With Advanced Ovarian Cancer

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Completed
51 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡